Patents by Inventor Jingkang Shen
Jingkang Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160145220Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.Type: ApplicationFiled: January 12, 2016Publication date: May 26, 2016Applicants: MITSUBISHI TANABE PHARMA CORPORATION, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.Inventors: Toru IIJIMA, Hiroshi SUGAMA, Takayuki KAWAGUCHI, Jingkang SHEN, Guangxin XIA, Jianshu XIE, Miki HIRAI
-
Publication number: 20160137640Abstract: This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumours associated with abnormal protein tyrosine kinase.Type: ApplicationFiled: June 18, 2014Publication date: May 19, 2016Inventors: Jingkang Shen, Meiyu Geng, Jian Ding, Bing Xiong, Jing Al, Yuchi Ma, Xin Wang, Xia Peng, Yuelei Chen, Danqi Chen, Tao Meng, Lanping Ma, Yinchun Ji
-
Patent number: 9278944Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.Type: GrantFiled: March 15, 2012Date of Patent: March 8, 2016Assignees: MITSUBISHI TANABE PHARMA CORPORATION, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.Inventors: Toru Iijima, Hiroshi Sugama, Takayuki Kawaguchi, Jingkang Shen, Guangxin Xia, Jianshu Xie, Miki Hirai
-
Publication number: 20150368274Abstract: The present invention belongs to the field of pharmaceutical Chemistry. In particular, the present invention relates to a pyridopyrimidine or pyrimidopyrimidine compound as represented by general formula (I), or an isomer thereof or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, a preparation method, a pharmaceutical composition and uses thereof in preparing a mTOR inhibitor. As a mTOR inhibitor, the compound or the pharmaceutical composition thereof can be used for treating a disease or condition due to PI3K-AKT-mTOR signalling pathway malfunction.Type: ApplicationFiled: September 1, 2015Publication date: December 24, 2015Inventors: Jingkang Shen, Ke Yu, Tao Meng, Lanping Ma, Lanfang Meng, Xin Wang, Yiyi Chen, Arie Zask
-
Publication number: 20150232459Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R1 is a cycloalkyl group or an alkyl, R22 is an optionally substituted aryl and the like, R is a lower alkyl group, R3, R4, R5 and R6 are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 13, 2013Publication date: August 20, 2015Applicants: Shanghai Pharmaceuticals Holding CO., LTD., MITSUBISHI TANABE PHARMA CORPORATIONInventors: Toru Iijima, Yoichi Takahashi, Miki Hirai, Hiroshi Sugama, Yuko Togashi, Jingkang Shen, Guangxin Xia, Huixin Wan
-
Patent number: 8975252Abstract: The present invention provides a morpholine derivative of the formula [I]; wherein R1 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; R2 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R3, R4, R5 and R6 are the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group; or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.Type: GrantFiled: June 16, 2008Date of Patent: March 10, 2015Assignees: Shanghai Pharmaceuticals Holding Co., Ltd., Mitsubishi Tanabe Pharma CorporationInventors: Hidenori Akatsuka, Hiroshi Sugama, Nobumasa Awai, Takayuki Kawaguchi, Yoichi Takahashi, Toru Iijima, Jingkang Shen, Guangxin Xia, Jianshu Xie
-
Patent number: 8871777Abstract: The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof and to the pharmaceutical composition as well as the preparation method of the compounds. The compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like.Type: GrantFiled: December 10, 2009Date of Patent: October 28, 2014Assignees: Topharman Shanghai Co., Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Topharman Shandong Co., Ltd.Inventors: Zheng Liu, Jianfeng Li, Xiaojun Yang, Zhen Wang, Jinfeng Zhang, Yi Zhu, Guanghui Tian, Qing Jin, Jingkang Shen, Weiliang Zhu, Hualiang Jiang, Jingshan Shen
-
Publication number: 20140206687Abstract: Disclosed are as represented by Formula (I) a quinazoline derivative and a pharmaceutical acceptable salt thereof, or, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug of both. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivative, and an application thereof. The quinazoline derivative of the present invention is provided with improved anti-tumor activity.Type: ApplicationFiled: July 27, 2012Publication date: July 24, 2014Applicants: ZHEJIANG UNIVERSITY, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.Inventors: Guangxin Xia, Jingkang Shen, Yongping Yu, Wenteng Chen, Chunchun Zhang, Yu Hao, Jing Zhang, Bojun Li, Xuejun Liu
-
Publication number: 20140011807Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.Type: ApplicationFiled: March 15, 2012Publication date: January 9, 2014Applicants: SHANGHAI PHARMACEUTICALS HOLDING CO., LTD., MITSUBISHI TANABE PHARMA CORPORATIONInventors: Toru Iijima, Hiroshi Sugama, Takayuki Kawaguchi, Jingkang Shen, Guangxin Xia, Jianshu Xie
-
Patent number: 8501762Abstract: The present invention relates to tetrahydroprotoberberines of the formula (I) and the physiologically acceptable salts thereof. The invention also relates to the use of the compounds of the formula (I) or pharmaceutically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with dopamine receptor ligand, such as schizophrenia.Type: GrantFiled: July 7, 2006Date of Patent: August 6, 2013Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Topharman Shanghai Co., Ltd.Inventors: Jianfeng Li, Aixiang Liu, Xinjian Chen, Guozhang Jin, Tiema Yan, Rongxia Zhang, Yi Zhu, Yanjun Pan, Jingshan Shen, Jingkang Shen
-
Publication number: 20130163873Abstract: A system and method of detecting separator lines in a web page may include determining coordinates of visible web elements on a web page, generating an edge image of the web page based on the coordinates of the web elements, filtering edges belonging to non-separator line elements within the edge image, detecting horizontal lines within the edge image, detecting vertical lines within the edge image, and filtering short lines within the edge image. A system for detecting separator lines in a web page may include a memory device, and a processor communicatively coupled to the memory, in which the processor determines coordinates of visible web elements on a web page, generates an edge image of the web page based on the coordinates of the web elements, filters edges belonging to non-separator line elements within the edge image, detects horizontal lines within the edge image, detects vertical lines within the edge image, and filters short lines within the edge image.Type: ApplicationFiled: July 30, 2010Publication date: June 27, 2013Inventors: Zhao Qingjie, Jianfeng Li, Ruisheng Xiong, Jingshan Shen, Weiliang Zhu, Hualiang Jiang, Jingkang Shen, Kyoung Tai No, Han Jo Kim, Ky-Youb Nam, Baik Lin Seong, Woo Jin Shin
-
Publication number: 20110301109Abstract: The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof and to the pharmaceutical composition as well as the preparation method of the compounds. The compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like.Type: ApplicationFiled: December 10, 2009Publication date: December 8, 2011Applicants: TOPHARMAN SHANGHAI CO., LTD.Inventors: Zheng Liu, Jianfeng Li, Xiaojun Yang, Zhen Wang, Jinfeng Zhang, Yi Zhu, Guanghui Tian, Qing Jin, Jingkang Shen, Weiliang Zhu, Hualiang Jiang, Jingshan Shen
-
Publication number: 20100240644Abstract: The present invention provides a morpholine derivative of the formula [I]; wherein R1 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; R2 is a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R3, R4, R5 and R6 are the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group; or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.Type: ApplicationFiled: June 16, 2008Publication date: September 23, 2010Inventors: Hidenori Akatsuka, Hiroshi Sugama, Nobumasa Awai, Takayuki Kawaguchi, Yoichi Takahashi, Toru Iijima, Jingkang Shen, Guangxin Xia, Jianshu Xie
-
Patent number: 7662860Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.Type: GrantFiled: December 2, 2005Date of Patent: February 16, 2010Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Lead Discovery Pharmaceuticals Limited CompanyInventors: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye
-
Publication number: 20090149488Abstract: The present invention relates to tetrahydroprotoberberines of the formula (I) and the physiologically acceptable salts thereof. The invention also relates to the use of the compounds of the formula (I) or pharmaceutically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with dopamine receptor ligand, such as schizophrenia.Type: ApplicationFiled: July 7, 2006Publication date: June 11, 2009Applicants: Shanghai Institute of Materia Medica, Chinese Academy of Science, Topharman Shanghai Co., Ltd.Inventors: Jianfeng Li, Aixiang Liu, Xinjian Chen, Guozhang Jin, Tiema Yan, Rongxia Zhang, Yi Zhu, Yanjun Pan, Jingshan Shen, Jingkang Shen
-
Publication number: 20060142383Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.Type: ApplicationFiled: December 2, 2005Publication date: June 29, 2006Inventors: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye
-
Patent number: 5929084Abstract: The present invention relates to novel huperzine A derivatives of formula (II), wherein Y is ##STR1## or R" and Y together form .dbd.CH; R is (C.sub.1 -C.sub.5) alkyl, ##STR2## wherein n is 0 or 1, X is H, (C.sub.1 -C.sub.5) alkyl; (C.sub.1 -C.sub.5) alkyloxy; nitro, halogen, carboxy, alkyloxycarbonyl, hydroxymethyl, hydroxy, amino substituted by bis-(C.sub.1 -C.sub.5) alkyl; --(CH.sub.2).sub.m COOZ, wherein m=0-5, Z is H or (C.sub.1 -C.sub.5) alkyl; --CH.dbd.CH--G, wherein G is phenyl, furanyl, carboxy, alkyloxycarbonyl; and dihydro- or tetrahydro-pyridyl substituted by (C.sub.1 -C.sub.5) alkyl at the nitrogen atom; R' is H, (C.sub.1 -C.sub.5) alkyl, pyridoyl, benzoyl substituted by (C.sub.1 -C.sub.5) alkyloxy; R" is H or (C.sub.1 -C.sub.5) alkyl; processes for their use as acetylcholinesterase inhibitor.Type: GrantFiled: June 27, 1997Date of Patent: July 27, 1999Assignee: Shangahi Institute of Materia Medica Chinese Academy of SciencesInventors: Dayuan Zhu, Xican Tang, Jinlai Lin, Cheng Zhu, Jingkang Shen, Guansong Wu, Shanhao Jiang, Takuji Yamaguchi, Kazuhiro Tanaka, Takeshi Wakamatsu, Hiroaki Nishimura